Levothyroxine sodium

Levothyroxine sodium  is White Solid

Levothyroxine Sodium is the sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.|The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

On August 14, 1997, the FDA declared levothyroxine sodium tablets a “new drug.” On February 15, 2017, the FDA approved levothyroxine sodium (brand name: Tirosint-SOL, developed by IBSA Pharma Inc.) oral solution for hypothyroidism and pituitary thyroid-stimulating hormone (TSH) suppression. Subsequently, the FDA approved two changes to the labeling of levothyroxine sodium (Tirosint-SOL, IBSA). The first change was for use in combination with a proton pump inhibitor (PPI). The second adjustment was the timing of levothyroxine sodium administration. The approved labeling changes were based on the results of two clinical studies that found no interaction between levothyroxine sodium and PPIs, and the same results were shown when administered 15 minutes and 30 minutes before breakfast. This led to the approval to label levothyroxine sodium as the only FDA-approved LT4 therapy that does not have label interactions with PPIs and can be taken 15 minutes before breakfast.

ChEBI: The sodium salt of L-thyoxine. It is used as replacement therapy in the treatment of hypothyroidism.

Levothyroxine sodium,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-2-tyrosinemonosodium salt, hydrate (Synthroid, Letter, Levoxine,Levoid), is the sodium salt of the levo isomer of thyroxine,which is an active physiological principle obtained from thethyroid gland of domesticated animals used for food by humans.It is also prepared synthetically. The salt is a light yellow,tasteless, odorless powder. It is hygroscopic but stablein dry air at room temperature. It is soluble in alkali hydroxides,1:275 in alcohol, and 1:500 in water, to give a pH ofabout 8.9.

One of the thyroid hormones involved in the maintenance of metabolic homeostasis. Synthesized and stored as amino acid residues of thyroglobulin, the major protein component of the thyroid follicular colloid. Synthesis and secretion are regulated by the pituitary hormone (TSH). Deiodinated in peripheral tissues to the active metabolite, liothyronine. The D-form has very little activity as a thyroid hormone, but has been used to treat hyperlipidemia.

Molecular Weight:888.93
Hydrogen Bond Donor Count:7
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:5
Exact Mass:888.7215
Monoisotopic Mass:888.7215
Topological Polar Surface Area:101
Heavy Atom Count:30
Complexity:426
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:7
Compound Is Canonicalized:Yes